The goal of this educational initiative is to equip oncology care teams with the knowledge and clinical decision-making tools needed to optimize the selection, sequencing, and safety management of HER2-directed ADCs across tumor types. Despite the expanded indications and tumor-agnostic approvals of agents such as T-DXd, significant gaps remain in HER2 reassessment practices, therapeutic sequencing frameworks, and adverse event management particularly in non-breast solid tumors such as gynecologic, gastrointestinal, and lung cancers.
Credit & MOC Details
Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.
Credit types
MOC types
FDA REMS
Qualifies for MIPS
Target Specialties
Pricing
79% of listed courses are free
11 of 14 courses listed here are free.
Collected from the provider’s public pages · source
- No reviews yet. Be the first to share yours.



